ArticleFrontiers in immunology2026
NOD1 modulates chronic obstructive pulmonary disease progression via FOXA1/NLRP3-mediated regulation of pyroptosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation and progressive airflow limitation. In this study, we established cellular models of COPD using bronchial epithelial cells and also constructed animal models to verify the protective effect of NOD1 knockout on lung tissue in COPD model mice, aiming to elucidate the molecular events linking increased NOD1 expression to inflammatory cell death. Transcriptomic and functional analyses revealed that NOD1 promotes pyroptosis in COPD via the FOXA1-NLRP3 signaling axis, with the PI3K-Akt pathway mediating these effects. Mechanistically, NOD1 suppresses FOXA1, leading to upregulation of NLRP3 and enhanced release of pro-inflammatory cytokines IL-18 and IL-1β. Knockdown of NOD1 alleviated pyroptosis and improved cell survival, effects reversed by NLRP3 overexpression. In conclusion, our findings identify the NOD1-FOXA1-NLRP3 axis as a key driver of inflammatory cell death in COPD, advancing our understanding of disease pathogenesis and highlighting potential molecular targets for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.